Skip to main content
. Author manuscript; available in PMC: 2024 Sep 15.
Published in final edited form as: Clin Cancer Res. 2024 Mar 15;30(6):1189–1199. doi: 10.1158/1078-0432.CCR-23-1957

Table 2.

Patient data in the Immunotherapy TMA group

Overall (N=54)
Age
Mean (SD) 70.9 (8.5)
Range 50.0 – 89.0
Sex
Female 15 (27.8%)
Male 39 (72.2%)
Immunosuppression
N 47 (87.0%)
Y 7 (13.0%)
IMTX agent
Anti-PD-1 monotherapy 37 (68.5%)
Anti-PD-1/Anti-CTLA-4 therapy 2 (3.7%)
Anti-PD-L1 therapy 15 (27.8%)
Viral status
Positive 28 (51.9%)
Negative 22 (40.7%)
No data 4 (7.4%)

TMA cohort